Nuvation Bio Inc.NUVB stock score: 40/100
$3.81 · +0.79% · Scored Nov 19, 2026
- Technical
- 30
- Fundamental
- 42
- News
- 56
The reading
Nuvation Bio (NUVB) scores 40 out of 100, which reads weak, higher than 23% of Healthcare stocks and 22% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 42, technicals 30.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 13 and contrarian oscillators 70 — a split worth reading before trusting the technical total.
News sentiment is neutral at 56; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 36 to 55, and it is down 13 points over the period.
About Nuvation Bio
Nuvation Bio (NUVB) is a commercial-stage biopharmaceutical company that develops and sells targeted cancer therapies. Its marketed drug, IBTROZI, is a pill for adults with advanced non-small cell lung cancer driven by ROS1 gene fusions, and it gained the drug through its acquisition of AnHeart Therapeutics. Nuvation sells IBTROZI directly in the United States, while partners handle the drug in other markets, including China, Japan and Europe. Its main pipeline candidate, safusidenib, is an IDH1 inhibitor in late-stage testing for IDH1-mutant glioma, a type of brain tumor, and the company also has earlier programs, including a drug-drug conjugate. Nuvation earns revenue from IBTROZI product sales in the United States and from royalties, milestones and supply payments from regional partners, and it has funded development with cash on hand and financing.
In ROS1-positive lung cancer, Nuvation competes with Bristol Myers Squibb, Pfizer and Roche, which sell other ROS1-targeted drugs, while in IDH-mutant glioma it would compete with Servier’s Voranigo. Its edge rests on clinical data showing durable responses, including in patients whose cancer has spread to the brain, and on a focused commercial team aimed at a small group of oncologists. Investors who follow NUVB stock tend to watch IBTROZI sales and new patient starts. Approvals and launches by partners outside the United States are closely followed. Progress of the safusidenib late-stage trial, operating expenses and cash runway are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward NUVB’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
42Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
5-year earnings growth evaluates long-term profit trajectory and consistency.
37 weighted scorers; 2 had no data today and are left out rather than counted as zero.
Technical · daily
21Pulling it up
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Holding it back
S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.
Where the price sits between its 52-week low and high.
Performance versus SPY compares the stock's returns to the S&P 500 index.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 56
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 38 | 1 |
| Daily | 21 | 3 |
| Weekly | 27 | 2 |
| Monthly | 42 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 40 |
| Nov 18, 2026 | 40 |
| Nov 17, 2026 | 40 |
| Nov 16, 2026 | 40 |
| Nov 15, 2026 | 40 |
| Nov 14, 2026 | 41 |
| Nov 13, 2026 | 41 |
| Nov 12, 2026 | 38 |
| Nov 11, 2026 | 39 |
| Nov 10, 2026 | 37 |
| Nov 8, 2026 | 37 |
| Nov 7, 2026 | 37 |
| Nov 6, 2026 | 36 |
| Nov 5, 2026 | 37 |
| Nov 4, 2026 | 39 |
| Nov 3, 2026 | 43 |
| Nov 2, 2026 | 43 |
| Nov 1, 2026 | 43 |
| Oct 31, 2026 | 42 |
| Oct 30, 2026 | 41 |
| Oct 29, 2026 | 41 |
| Oct 28, 2026 | 39 |
| Oct 27, 2026 | 39 |
| Oct 26, 2026 | 39 |
| Oct 25, 2026 | 39 |
| Oct 24, 2026 | 39 |
| Oct 23, 2026 | 39 |
| Oct 22, 2026 | 41 |
| Oct 21, 2026 | 43 |
| Oct 20, 2026 | 42 |
| Oct 19, 2026 | 40 |
| Oct 18, 2026 | 40 |
| Oct 17, 2026 | 40 |
| Oct 16, 2026 | 40 |
| Oct 15, 2026 | 42 |
| Oct 14, 2026 | 40 |
| Oct 13, 2026 | 42 |
| Oct 12, 2026 | 43 |
| Oct 11, 2026 | 44 |
| Oct 10, 2026 | 44 |
| Oct 9, 2026 | 44 |
| Oct 8, 2026 | 43 |
| Oct 7, 2026 | 42 |
| Oct 6, 2026 | 43 |
| Oct 5, 2026 | 42 |
| Oct 4, 2026 | 43 |
| Oct 3, 2026 | 42 |
| Oct 2, 2026 | 43 |
| Oct 1, 2026 | 45 |
| Sep 30, 2026 | 47 |
| Sep 29, 2026 | 45 |
| Sep 28, 2026 | 45 |
| Sep 27, 2026 | 47 |
| Sep 26, 2026 | 47 |
| Sep 25, 2026 | 47 |
| Sep 24, 2026 | 48 |
| Sep 23, 2026 | 48 |
| Sep 22, 2026 | 50 |
| Sep 21, 2026 | 49 |
| Sep 20, 2026 | 48 |
| Sep 19, 2026 | 48 |
| Sep 18, 2026 | 48 |
| Sep 17, 2026 | 50 |
| Sep 16, 2026 | 47 |
| Sep 15, 2026 | 46 |
| Sep 14, 2026 | 47 |
| Sep 13, 2026 | 48 |
| Sep 12, 2026 | 48 |
| Sep 11, 2026 | 48 |
| Sep 10, 2026 | 49 |
| Sep 9, 2026 | 50 |
| Sep 8, 2026 | 51 |
| Sep 7, 2026 | 52 |
| Sep 6, 2026 | 52 |
| Sep 5, 2026 | 52 |
| Sep 4, 2026 | 52 |
| Sep 3, 2026 | 55 |
| Sep 2, 2026 | 53 |
| Sep 1, 2026 | 52 |
| Aug 31, 2026 | 51 |
| Aug 30, 2026 | 51 |
| Aug 29, 2026 | 51 |
| Aug 28, 2026 | 51 |
| Aug 27, 2026 | 53 |
| Aug 26, 2026 | 54 |
| Aug 25, 2026 | 54 |
| Aug 24, 2026 | 51 |
| Aug 23, 2026 | 53 |
| Aug 22, 2026 | 53 |
Key facts
- Market cap
- $1.3B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.73
- Risk grade (1–10)
- 10
- Next earnings
- Nov 4, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| NBTX Nanobiotix | $1.4B | 48 |
| IMCR Immunocore Holdings | $1.4B | 51 |
| TYRA Tyra Biosciences | $1.4B | 31 |
| NTLA Intellia Therapeutics | $1.3B | 33 |
| INVA Innoviva | $1.3B | 63 |
| LBRX LB Pharmaceuticals | $1.3B | 41 |
Questions
What is NUVB's stock rating today?
NUVB scores 40/100 (Weak) as of Nov 19, 2026: technical 30, fundamental 42, and news sentiment 56, which is shown but not counted. Scores are recomputed every night.
What does Nuvation Bio do?
Nuvation Bio (NUVB) is a commercial-stage biopharmaceutical company that develops and sells targeted cancer therapies. Its marketed drug, IBTROZI, is a pill for adults with advanced non-small cell lung cancer driven by ROS1 gene fusions, and it gained the drug through its acquisition of AnHeart Therapeutics.
Is NUVB stock a buy?
The score is not a buy or sell recommendation. A 40 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the NUVB score calculated?
99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/nuvb/"><img src="https://stocksscores.com/stocks/nuvb/badge.svg" alt="NUVB stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/nuvb/)